Study shows efficacy of dual-HER2 targeted therapy for patients with HER2-positive colorectal cancer

PRESS RELEASE Research Findings

15/11/2021

National Cancer Center Japan

Investigator-initiated trial based on GI-SCREEN-Japan/GOZILA study may lead to the world's first effective treatment for HER2-positive colorectal cancer

Related News

Anti-Cancer Agent Herceptin Approved for Additional Indication of Salivary Gland Cancer

TOKYO, November 25, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it obtained approval from the Ministry of Health, Labour and...

03/12/2021

PRESS RELEASE Corporate Announcements

Trastuzumab deruxtecan (DS-8201/T-DXd) ได้รับการรับรอง “Breakthrough Therapy Designation" จาก FDA ในฐานะ second-line treatment สำหรับผู้ป่วยมะเร็งเต้านม HER2-positive

Daiichi Sankyo Co., Ltd. (สำนักงานใหญ่: Chuo-ku, Tokyo ต่อจากนี้จะเรียกว่า "Daiichi") และ AstraZeneca (สำนักงานใหญ่: Cambridge, สหราชอาณาจักร) ได้เปิด...

29/10/2021

PRESS RELEASE FDA Approval

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpre...

29/04/2022

PRESS RELEASE FDA Approval

Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approve...

20/05/2022

PRESS RELEASE FDA Approval

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us